Physician profile
Joy Rosconi
NPI 1255775656
$624.59
in general payments reported to CMS, 2019-2025
13 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $277 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.60 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $140.45 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $110.38 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $109.26 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $37.91 | 2025 | Voquezna |
| Amgen INC. | $36.79 | 2024-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $34.72 | 2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $33.93 | 2025 | Wegovy |
| Pfizer INC. | $24.85 | 2024 | |
| Vital Connect, INC | $23.86 | 2024 | Vitalpatch Rtm |
| Merck Sharp & Dohme LLC | $20.20 | 2025 | Capvaxive, Gardasil 9 |
| Sumitomo Pharma America, INC. | $17.86 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $17.82 | 2025 | Rexulti |
| Abbvie INC. | $16.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Rosconi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.